Diabetes & Metabolism Journal

Review

Metabolic Risk/Epidemiology
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review: Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang; Diabetes Metab J. 2024;48(2):184-195. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2023.0168

5,552 View
571 Download
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.

Citations

Citations to this article as recorded by

Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT
Eu Jeong Ku, Bongseong Kim, Kyungdo Han, Seung-Hwan Lee, Hyuk-Sang Kwon
Cardiovascular Diabetology.2024;[Epub] CrossRef
The role of DGAT1 and DGAT2 in tumor progression via fatty acid metabolism: A comprehensive review
Leisheng Wang, Shiwei Xu, Mengzhen Zhou, Hao Hu, Jinyou Li
International Journal of Biological Macromolecules.2024; 278: 134835. CrossRef
An exploratory investigation of lipid-lowering potential of spirulina ( Arthrospira platensis ) targeting apoprotein-E in chronic hyperlipidemic wistar albino rats
Anum Nazir, Mahr Un Nisa, Mohamed H. Mahmoud, Ahmed M. El-Gazzar, Eliasse Zongo
Cogent Food & Agriculture.2024;[Epub] CrossRef
Advances in Understanding Diabetic Kidney Disease Progression and the Mechanisms of Acupuncture Intervention
Jinyi Shan, Ziyi Cao, Siming Yu
International Journal of General Medicine.2024; Volume 17: 5593. CrossRef

First
Prev
Page of 1
Next
Last

Search